搜索范围
V900339
应用筛选条件
关键词:'V900339'
显示 1-30 #N/A 139 条结果 关于 "V900339" 范围 论文
Aziz Nazha et al.
American journal of hematology, 88(11), 961-966 (2013-07-24)
Clofarabine is a second generation nucleoside analogue with activity in adults with acute myeloid leukemia (AML). A phase I trial of clofarabine, idarubicin, and cytarabine (CIA) in relapsed and refractory AML had shown an overall response rate (ORR) of 48%.
Cyril Lervat et al.
Pediatric blood & cancer, 61(3), 473-478 (2013-08-24)
Describe the epidemiology, clinical profiles and outcomes associated with head and neck (H&N) involvement in children/adolescents with B-cell non-Hodgkin lymphoma (B-NHL). Analysis of children/adolescents with H&N B-NHL prospectively enrolled in the SFOP LMB-89 trial (July 1989-June 1996). One hundred and
Sachit A Patel et al.
Journal of pediatric hematology/oncology, 36(6), 491-494 (2013-12-11)
Hematopoietic stem cell transplantation (HSCT) remains the only curative option for most patients with juvenile myelomonocytic leukemia (JMML). However, persistent disease and relapse rates after transplant range from 26% to 58%. We report the successful use of second HSCT after
Sarah A Buckley et al.
American journal of hematology, 89(4), 423-428 (2014-01-03)
Intensive chemotherapy for newly diagnosed acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) is associated with significant treatment-related morbidity and mortality. Herein, we investigate how pretreatment characteristics relate to early adverse outcomes in such patients, studying 205 consecutive individuals receiving
Elias Jabbour et al.
American journal of hematology, 89(4), 395-398 (2014-01-01)
Outcomes of patients with acute myeloid leukemia (AML) who are refractory to high-dose Cytarabine (HiDAC)-based induction are dismal. Allogeneic hematopoietic stem cell transplantation (AHSCT) as initial salvage may be effective and potentially superior to conventional salvage chemotherapy. Eighteen percent (285
Koji Kato et al.
Pediatric blood & cancer, 61(4), 712-716 (2014-01-01)
The conventional conditioning regimen for patients with leukemia prior to allogeneic stem cell transplantation is myeloablation to eradicate residual leukemic cells and host immunocompetent cells. This helps prevent leukemic relapse as well as rejection after transplantation. A myeloablative conditioning regimen
Elizabeth Anderson et al.
Leukemia research, 37(6), 690-696 (2013-03-12)
This study evaluates an in vitro biosensor assay capable of detecting the intracellular levels of the tri-phosphorylated form of cytarabine (Ara-CTP) within one working day. The biosensor predicted the response of seven leukaemic cell lines with varying known sensitivities to
Yuki Kojima et al.
Japanese journal of clinical oncology, 44(4), 318-323 (2014-02-22)
Acquired immunodeficiency syndrome-related non-Hodgkin lymphoma is treated similarly to non-acquired immunodeficiency syndrome lymphoma, but it is not clear whether highly intensive regimens are beneficial for acquired immunodeficiency syndrome-related Burkitt lymphoma. We conducted a multicenter retrospective survey to clarify the clinical
Breakthrough Fusarium solani infection in a patient with acute myeloid leukemia receiving posaconazole prophylaxis.
Cheng-Han Wu et al.
Annals of hematology, 93(6), 1079-1081 (2013-10-31)
Eric R Gamazon et al.
Blood, 121(21), 4366-4376 (2013-03-30)
A whole-genome approach was used to investigate the genetic determinants of cytarabine-induced cytotoxicity. We performed a meta-analysis of genome-wide association studies involving 523 lymphoblastoid cell lines (LCLs) from individuals of European, African, Asian, and African American ancestry. Several of the
Terzah M Horton et al.
Pediatric blood & cancer, 61(10), 1754-1760 (2014-07-01)
This Phase 2 study tested the tolerability and efficacy of bortezomib combined with reinduction chemotherapy for pediatric patients with relapsed, refractory or secondary acute myeloid leukemia (AML). Correlative studies measured putative AML leukemia initiating cells (AML-LIC) before and after treatment.
Michaela Liedtke et al.
Leukemia research, 38(12), 1441-1445 (2014-12-03)
The survival of patients with relapsed or refractory acute lymphoblastic leukemia (ALL) is poor. We performed a retrospective analysis of 40 patients treated with five days of mitoxantrone 8mg/m(2)/day, etoposide 100mg/m(2)/day, and cytarabine 1000mg/m(2)/day (MEC). The complete remission rate was
Annamaria Buschini et al.
Occupational and environmental medicine, 70(11), 789-794 (2013-10-22)
People who handle antineoplastic drugs, many of which classified as human carcinogens by International Agency for Research on Cancer, are exposed to low doses in comparison with patients; however, the long duration of exposure could lead to health effects. The
Skjalg Bruheim et al.
Anticancer research, 33(9), 3615-3621 (2013-09-12)
The objective of the present study was to determine the in vivo antitumor activity of elacytarabine, the 5'-elaidic acid ester of arabinofuranosyl cytidine, alone and in combination with bevacizumab, cetuximab and trastuzumab in Vascular endothelial growth factor (VEGF), Epidermal growth
F Fichel et al.
Annales de dermatologie et de venereologie, 140(3), 209-214 (2013-03-08)
Herein, we report the first case of kaposiform haemangioendothelioma (KHE) associated with acute B-lymphoblastic leukemia (B-ALL). A five-month-old infant presented a plaque of angiomatous appearance on the forearm that had increased in volume since birth, as well as pallor and
When the eye gives it all: diagnosis of relapsing acute myeloblastic leukemia with anterior chamber tap of a chronic hypopyon.
Valerie Touitou et al.
American journal of hematology, 89(8), 858-859 (2014-08-29)
Hiba Ahmad Zahreddine et al.
Nature, 511(7507), 90-93 (2014-05-30)
Drug resistance is a major hurdle in oncology. Responses of acute myeloid leukaemia (AML) patients to cytarabine (Ara-C)-based therapies are often short lived with a median overall survival of months. Therapies are under development to improve outcomes and include targeting
Kenneth F Bradstock et al.
British journal of haematology, 167(5), 618-625 (2014-08-22)
Gastrointestinal toxicity, including oral mucositis, is a frequent complication of intensive combination chemotherapy for acute myeloid leukaemia (AML) and contributes substantially to treatment-related mortality. We conducted a placebo-controlled randomized trial to evaluate the efficacy of palifermin (keratinocyte growth factor), given
Julie M Vose et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 31(13), 1662-1668 (2013-03-13)
This clinical trial evaluated standard-dose radioimmunotherapy with a chemotherapy-based transplantation regimen followed by autologous hematopoietic cell transplantation versus rituximab with the same regimen in patients with relapsed diffuse large B-cell lymphoma (DLBCL). Patients with chemotherapy-sensitive persistent or relapsed DLBCL were
Prescrire international, 23(148), 92-94 (2014-05-27)
Acute myeloid leukaemia is a life-threatening disease. Its incidence increases with age. There is no consensus on treatment for patients over 60 years of age who cannot receive first-line high-dose chemotherapy. Options include low-dose cytarabine, other non-intensive chemotherapy regimens, or
Noha M El Husseiny et al.
Annals of hematology, 93(1), 141-145 (2013-07-31)
Multiple myeloma is a neoplasm of plasma cells that results in the overproduction of light and heavy chain monoclonal immunoglobulins. The incidence rate increases with age, particularly after 40 years, and is higher in men. To determine the clinical and
Michael E Rytting et al.
Cancer, 120(23), 3660-3668 (2014-07-22)
Various trials have reported improved outcomes for adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL) who received treatment with pediatric-based regimens. Those reports prompted the current investigation of the pediatric augmented Berlin-Frankfurt-Münster (ABFM) regimen in AYA patients. The
Mutant DNMT3A clone evading chemotherapy and infiltrating central nervous system in a patient with molecularly good-risk acute myeloid leukemia.
Yi-Yang Chen et al.
Annals of hematology, 93(8), 1441-1442 (2013-12-18)
Matthew Trendowski et al.
Anticancer research, 35(1), 65-76 (2015-01-01)
Cytochalasin B is a mycogenic toxin that preferentially damages malignant cells through multiple mechanisms. The microfilament-disrupting agent inhibits cytokinesis, producing enlarged and multinucleated neoplastic cells without enlarging or producing multinucleated normal cells. In addition, cytochalasin B has been shown to
Lionel Adès et al.
Current hematologic malignancy reports, 1(2), 122-125 (2006-06-01)
Until the late 1980s, chemotherapy with anthracyclines and cytarabine (AraC) was the only treatment approach for acute promyelocytic leukemia (APL), as for other types of acute myeloid leukemia. Many studies have shown that treatment with all-trans retinoic acid (ATRA), followed
Daniel Nowak et al.
Experimental hematology, 43(1), 32-43 (2014-12-03)
The use of genome-wide copy-number analysis and massive parallel sequencing has revolutionized the understanding of the clonal architecture of pediatric acute lymphoblastic leukemia (ALL) by demonstrating that this disease is composed of highly variable clonal ancestries following the rules of
Bob Löwenberg
Blood, 121(1), 26-28 (2013-01-05)
High-dose cytarabine applied during remission induction or as consolidation after attainment of a complete remission has become an established element in the treatment of adults with acute myeloid leukemia. Recent evidence has challenged the need for these exceptionally high-dose levels
Hagop M Kantarjian et al.
Cancer, 119(14), 2611-2619 (2013-04-23)
In this phase 2 study, the authors evaluated the efficacy, safety, and tolerability of the Aurora B kinase inhibitor barasertib compared with low-dose cytosine arabinoside (LDAC) in patients aged ≥ 60 years with acute myeloid leukemia (AML). Patients were randomized
Patrick G Morris et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 31(31), 3971-3979 (2013-10-09)
A multicenter phase II study was conducted to assess the efficacy of rituximab, methotrexate, procarbazine, and vincristine (R-MPV) followed by consolidation reduced-dose whole-brain radiotherapy (rdWBRT) and cytarabine in primary CNS lymphoma. Patients received induction chemotherapy with R-MPV (five to seven
Arne Kolstad et al.
Blood, 123(19), 2953-2959 (2014-03-22)
The main objective of the MCL3 study was to improve outcome for patients not in complete remission (CR) before transplant by adding (90)Y-ibritumomab-tiuxetan (Zevalin) to the high-dose regimen. One hundred sixty untreated, stage II-IV mantle cell lymphoma patients <66 years
1/5